All In Biotech

Drug Trial Radar · NCT02207244

A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment

A Phase 3, Multicenter, Randomized, Double-blind, Placebo and Active Comparator-controlled Study Evaluating the Efficacy and Safety of Guselkumab for the Treatment of Subjects With Moderate to Severe Plaque-type Psoriasis With Randomized Withdrawal and Retreatment

Last checked: Nov 20, 2026Latest source record: Jul 22, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 992 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

992

Actual

Start

Nov 3, 2014

Primary completion

Oct 1, 2015

Study completion Jul 1, 2020

Sponsor

Lead sponsor
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Aug 4, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, and tolerability of guselkumab (CNTO 1959) in the treatment of participants with moderate to severe plaque-type psoriasis (scaly skin rash).

Conditions

  • Psoriasis

Interventions

  • Guselkumab 100 mgDrug

    100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.

  • Placebo for guselkumabDrug

    Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).

  • AdalimumabDrug

    80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.

  • Placebo for adalimumabDrug

    Placebo for adalimumab \[two 0.8 milliliter (mL) injections\] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of Cleared (0) or Minimal (1) in the Guselkumab Group Compared to the Placebo Group at Week 16Time frame: Week 16
  2. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response in the Guselkumab Group Compared to the Placebo Group at Week 16Time frame: Week 16

Locations

93 sites in 9 countries. Site status is shown where the registry gives one.

  • Site not named

    Birmingham, Alabama

  • Site not named

    Bakersfield, California

  • Site not named

    Los Angeles, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Monica, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Coral Gables, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Newnan, Georgia

  • Site not named

    Sandy Springs, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Rolling Meadows, Illinois

  • Site not named

    Skokie, Illinois

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Plainfield, Indiana

  • Site not named

    Louisville, Kentucky

  • Site not named

    Andover, Massachusetts

  • Site not named

    Fort Gratiot, Michigan

  • Site not named

    Troy, Michigan

  • Site not named

    St Louis, Missouri

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    New York, New York

  • Site not named

    Gahanna, Ohio

  • Site not named

    Norman, Oklahoma

  • Site not named

    Portland, Oregon

  • Site not named

    Pittsburgh, Pennsylvania

  • Site not named

    Johnston, Rhode Island

  • Site not named

    Arlington, Texas

  • Site not named

    Houston, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Seattle, Washington

  • Site not named

    Spokane, Washington

  • Site not named

    Benowa, Australia

  • Site not named

    Hectorville, Australia

  • Site not named

    Melbourne, Australia

  • Site not named

    Parkville, Australia

  • Site not named

    Westmead, Australia

  • Site not named

    Woolloongabba, Australia

  • Site not named

    Barrie, Ontario, Canada

  • Site not named

    Hamilton, Ontario, Canada

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.